Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05362773
Other study ID # CP-MGD024-01
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date July 13, 2022
Est. completion date March 2025

Study information

Verified date January 2024
Source MacroGenics
Contact Global Trial Manager
Phone 301-251-5172
Email info@macrogenics.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

CP-MGD024-01 is a Phase 1, open-label, multi-center study of MGD024 as a single agent in patients with select blood cancers that have not responded to treatment with standard therapies or who have relapsed after treatment. The study is designed to determine the safety, tolerability, pharmacokinetics (affect of the body on the drug), pharmacodynamic (affect of the drug on the body), immunogenicity (development of antibodies against the drug), and preliminary anti-cancer effect of MGD024. Patients will receive treatment with MGD024 in consecutive 28-day cycles for a study treatment period of up to 12 cycles (approximately 1 year) or until treatment or study discontinuation criteria are met. Response assessments will be performed after Cycle 1 and then after every even numbered cycle starting with Cycle 2 until progression or study treatment discontinuation. Patients will be checked for side effects throughout the study.


Recruitment information / eligibility

Status Recruiting
Enrollment 90
Est. completion date March 2025
Est. primary completion date March 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Adult patients at least 18 years of age, able to provide informed consent and willing to comply with all study procedures. - Patients with primary or secondary acute myeloid leukemia (AML), primary or secondary myelodysplastic syndrome (MDS), classical Hodgkin lymphoma (cHL), chronic myelogenous leukemia (CML), b-cell acute lymphocytic leukemia (B-ALL), hariy cell leukemia (HCL), advanced systemic mastocytosis (ASM), or blastic plasmacytoid dendritic cell neoplasm (BPDCM) - Relapsed after or refractory to at least one prior line of therapy and with no available potentially curative treatment option. - Evidence of CD123 expression - Eastern Cooperative Oncology Group (ECOG) performance status of = 2. - Life expectancy of at least 12 weeks. - Acceptable laboratory values, and heart function. - Continuing side effects of prior treatment are mild - Women and men of childbearing potential must agree to use highly effective forms of contraception throughout the study through 4 months after the last dose of MGD024. Exclusion Criteria: - Prior treatment with an anti-CD123-directed agent (except patients with BPDCN, who are allowed to have received prior tagraxofusp). - Known involvement of central nervous system (CNS) by the disease under investigation. - History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the patient's participation for the full duration of the trial, or is not in the best interest of the patient. - Systemic anti-cancer therapy, investigational therapy, corticosteroids or other immune suppressive drugs within 14 days of first dose - Vaccination with any live virus vaccine within 4 weeks prior to first dose. Inactivated annual influenza and SARS-CoV-2 vaccination are allowed.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
MGD024
MGD024 is a CD123 x CD3 bispecific DART® molecule designed to target CD123-expressing leukemic cells for elimination by CD3-expressing T lymphocytes.

Locations

Country Name City State
United States South Austin Medical Center Austin Texas
United States University of Maryland, Greenbaum Comprehensive Cancer Center Baltimore Maryland
United States Dana Farber Cancer Institute Boston Massachusetts
United States Colorado Blood Cancer Network Denver Colorado
United States Duke University Medical Center Durham North Carolina
United States START - Midwest Grand Rapids Michigan
United States Washington University School of Medicine Saint Louis Missouri

Sponsors (1)

Lead Sponsor Collaborator
MacroGenics

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of severe side effects in patients receiving MGD024 Observation of side effects determines the highest safe dose for further study First 28 days of the study
Primary Number and types of adverse events (AEs), including serious adverse events (SAEs), and AEs leading to treatment discontinuation. Observation of side effects determines the highest safe dose for further study Throughout study participation, up to 12 months.
Secondary Maximum concentration The highest concentration of MGD024 at the end of the infusion Day 1, 8,15, 22, 29, 36, 43, 50 and 57
Secondary Area under the concentration-time curve (AUC) Total body exposure to MGD024 Day 1, 8,15, 22, 29, 36, 43, 50 and 57
Secondary Anti-drug antibody formation Number of patients who develop antibodies against MDG024 Day 1, Day 15, Day 28, then every 28 days throughout the study, up to 12 months.
Secondary Overall response rate The proportion of patients with a complete response or a partial response to treatment Disease response assessment on Day 28, Day 56, then every 56 days throughout the study, up to 12 months.
Secondary Complete response rate The proportion of patient achieving a complete response according to disease-specific criteria Disease response assessment on Day 28, Day 56, then every 56 days throughout the study, up to 12 months.
Secondary Progression free survival The time between the first dose date to the date of first documented disease-specific progression or death from any cause Disease response is assessed approximately every 56 days throughout the study, up to 12 months.Assessed from Day 1 throughout the study until individual participant discontinuation, up to 12 months. Survival from Day 1 throughout the study.
Secondary Time to response The time between the first dose and the date of initial response. Disease response is assessed approximately every 56 days throughout the study, up to 12 months.
Secondary Duration of response The time between the date of initial response to the date of disease-specific progression or death from any cause Disease response is assessed approximately every 56 days throughout the study, up to 12 months.
Secondary Overall survival The time between the first dose date to the date of death from any cause Assessed from Day 1 throughout the study until individual participant study discontinuation, up to 12 months.
Secondary Number of participants with AEs and SAEs occurring after administration of tocilizumab Throughout study participation, up to 12 months.
Secondary Number of participants with changes in cytokines or C-reactive protein after administration of tocilizumab. Throughout study participation, up to 12 months.
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Terminated NCT04313881 - Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS) Phase 3
Recruiting NCT05088356 - Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft Phase 1
Recruiting NCT04003220 - Idiopathic Chronic Thrombocytopenia of Undetermined Significance : Pathogenesis and Biomarker
Completed NCT02916979 - Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG Phase 1
Active, not recruiting NCT03755414 - Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation Phase 1
Completed NCT00003270 - Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer Phase 2
Recruiting NCT04904588 - HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide Phase 2
Terminated NCT04866056 - Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF. Phase 1/Phase 2
Recruiting NCT04701229 - Haploinsufficiency of the RBM22 and SLU7 Genes in Del(5q) Myelodysplastic Syndromes
Suspended NCT04485065 - Safety and Efficacy of IBI188 With Azacitidine in Subjects With Newly Diagnosed Higher Risk MDS Phase 1
Recruiting NCT04174547 - An European Platform for Translational Research in Myelodysplastic Syndromes
Enrolling by invitation NCT04093570 - A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study Centers Phase 2
Completed NCT02508870 - A Study of Atezolizumab Administered Alone or in Combination With Azacitidine in Participants With Myelodysplastic Syndromes Phase 1
Completed NCT04543305 - A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies Phase 1
Recruiting NCT05384691 - Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions Phase 2
Recruiting NCT05365035 - A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts Phase 2
Recruiting NCT06008405 - Clinical Trial Evaluating the Safety of the TQB2928 Injection Combination Therapy Phase 1
Not yet recruiting NCT05969821 - Clonal Hematopoiesis of Immunological Significance
Withdrawn NCT05170828 - Cryopreserved MMUD BM With PTCy for Hematologic Malignancies Phase 1